Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: Results of a meta-analysis

Martin Farlow, Gary W. Small, Peter Quarg, Andreas Krause

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: Alzheimer's disease (AD) patients experiencing more rapid symptom progression are likely to have a poorer prognosis than those experiencing slow symptom progression. In a recent retrospective analysis, treatment effects of rivastigmine were more pronounced in AD patients with rapid cognitive decline than in those with slow cognitive decline. This warranted further investigation. Methods: Rapidly and slowly progressing patients were identified by rates of cognitive decline [≥4 points and <4 points, respectively, on the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog)] during 26 weeks of placebo treatment in four randomized controlled trials (weeks 0-26). This meta-analysis evaluated rates of cognitive decline in both subgroups during subsequent open-label rivastigmine 26-week extension studies (weeks 26-52). A longitudinal mixed effects model compared cognitive decline in rapidly and slowly progressing patients, including correction for possible regression to the mean. Results: 180 (75%) rapidly and 337 (78%) slowly progressing patients provided ADAS-cog data after 26 weeks of open-label rivastigmine treatment. Improvements in cognitive symptoms were observed during the first 12 weeks, which were more pronounced in patients with rapid progression than in those with slow progression. Rapidly progressing patients experienced significantly greater cognitive benefits than slowly progressing patients (p = 0.029), who experienced a modest decline in cognitive symptoms at the end of the study. Comment: Patients experiencing rapid symptom progression may receive greater benefit from rivastigmine than those with slow progression. In this study, cholinesterase inhibition appeared to be of particular utility in the management of AD patients whose symptoms were rapidly worsening.

Original languageEnglish
Pages (from-to)192-197
Number of pages6
JournalDementia and Geriatric Cognitive Disorders
Volume20
Issue number2-3
DOIs
StatePublished - Aug 2005

Fingerprint

Rivastigmine
Disease Progression
Meta-Analysis
Alzheimer Disease
Neurobehavioral Manifestations

Keywords

  • Alzheimer's disease
  • Cholinesterase inhibitor
  • Rapid progression
  • Rivastigmine

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Geriatrics and Gerontology

Cite this

Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression : Results of a meta-analysis. / Farlow, Martin; Small, Gary W.; Quarg, Peter; Krause, Andreas.

In: Dementia and Geriatric Cognitive Disorders, Vol. 20, No. 2-3, 08.2005, p. 192-197.

Research output: Contribution to journalArticle

@article{e372c5cd1c8a465481db25a36ca18dd0,
title = "Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: Results of a meta-analysis",
abstract = "Background: Alzheimer's disease (AD) patients experiencing more rapid symptom progression are likely to have a poorer prognosis than those experiencing slow symptom progression. In a recent retrospective analysis, treatment effects of rivastigmine were more pronounced in AD patients with rapid cognitive decline than in those with slow cognitive decline. This warranted further investigation. Methods: Rapidly and slowly progressing patients were identified by rates of cognitive decline [≥4 points and <4 points, respectively, on the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog)] during 26 weeks of placebo treatment in four randomized controlled trials (weeks 0-26). This meta-analysis evaluated rates of cognitive decline in both subgroups during subsequent open-label rivastigmine 26-week extension studies (weeks 26-52). A longitudinal mixed effects model compared cognitive decline in rapidly and slowly progressing patients, including correction for possible regression to the mean. Results: 180 (75{\%}) rapidly and 337 (78{\%}) slowly progressing patients provided ADAS-cog data after 26 weeks of open-label rivastigmine treatment. Improvements in cognitive symptoms were observed during the first 12 weeks, which were more pronounced in patients with rapid progression than in those with slow progression. Rapidly progressing patients experienced significantly greater cognitive benefits than slowly progressing patients (p = 0.029), who experienced a modest decline in cognitive symptoms at the end of the study. Comment: Patients experiencing rapid symptom progression may receive greater benefit from rivastigmine than those with slow progression. In this study, cholinesterase inhibition appeared to be of particular utility in the management of AD patients whose symptoms were rapidly worsening.",
keywords = "Alzheimer's disease, Cholinesterase inhibitor, Rapid progression, Rivastigmine",
author = "Martin Farlow and Small, {Gary W.} and Peter Quarg and Andreas Krause",
year = "2005",
month = "8",
doi = "10.1159/000087301",
language = "English",
volume = "20",
pages = "192--197",
journal = "Dementia and Geriatric Cognitive Disorders",
issn = "1420-8008",
publisher = "S. Karger AG",
number = "2-3",

}

TY - JOUR

T1 - Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression

T2 - Results of a meta-analysis

AU - Farlow, Martin

AU - Small, Gary W.

AU - Quarg, Peter

AU - Krause, Andreas

PY - 2005/8

Y1 - 2005/8

N2 - Background: Alzheimer's disease (AD) patients experiencing more rapid symptom progression are likely to have a poorer prognosis than those experiencing slow symptom progression. In a recent retrospective analysis, treatment effects of rivastigmine were more pronounced in AD patients with rapid cognitive decline than in those with slow cognitive decline. This warranted further investigation. Methods: Rapidly and slowly progressing patients were identified by rates of cognitive decline [≥4 points and <4 points, respectively, on the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog)] during 26 weeks of placebo treatment in four randomized controlled trials (weeks 0-26). This meta-analysis evaluated rates of cognitive decline in both subgroups during subsequent open-label rivastigmine 26-week extension studies (weeks 26-52). A longitudinal mixed effects model compared cognitive decline in rapidly and slowly progressing patients, including correction for possible regression to the mean. Results: 180 (75%) rapidly and 337 (78%) slowly progressing patients provided ADAS-cog data after 26 weeks of open-label rivastigmine treatment. Improvements in cognitive symptoms were observed during the first 12 weeks, which were more pronounced in patients with rapid progression than in those with slow progression. Rapidly progressing patients experienced significantly greater cognitive benefits than slowly progressing patients (p = 0.029), who experienced a modest decline in cognitive symptoms at the end of the study. Comment: Patients experiencing rapid symptom progression may receive greater benefit from rivastigmine than those with slow progression. In this study, cholinesterase inhibition appeared to be of particular utility in the management of AD patients whose symptoms were rapidly worsening.

AB - Background: Alzheimer's disease (AD) patients experiencing more rapid symptom progression are likely to have a poorer prognosis than those experiencing slow symptom progression. In a recent retrospective analysis, treatment effects of rivastigmine were more pronounced in AD patients with rapid cognitive decline than in those with slow cognitive decline. This warranted further investigation. Methods: Rapidly and slowly progressing patients were identified by rates of cognitive decline [≥4 points and <4 points, respectively, on the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog)] during 26 weeks of placebo treatment in four randomized controlled trials (weeks 0-26). This meta-analysis evaluated rates of cognitive decline in both subgroups during subsequent open-label rivastigmine 26-week extension studies (weeks 26-52). A longitudinal mixed effects model compared cognitive decline in rapidly and slowly progressing patients, including correction for possible regression to the mean. Results: 180 (75%) rapidly and 337 (78%) slowly progressing patients provided ADAS-cog data after 26 weeks of open-label rivastigmine treatment. Improvements in cognitive symptoms were observed during the first 12 weeks, which were more pronounced in patients with rapid progression than in those with slow progression. Rapidly progressing patients experienced significantly greater cognitive benefits than slowly progressing patients (p = 0.029), who experienced a modest decline in cognitive symptoms at the end of the study. Comment: Patients experiencing rapid symptom progression may receive greater benefit from rivastigmine than those with slow progression. In this study, cholinesterase inhibition appeared to be of particular utility in the management of AD patients whose symptoms were rapidly worsening.

KW - Alzheimer's disease

KW - Cholinesterase inhibitor

KW - Rapid progression

KW - Rivastigmine

UR - http://www.scopus.com/inward/record.url?scp=23944514049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944514049&partnerID=8YFLogxK

U2 - 10.1159/000087301

DO - 10.1159/000087301

M3 - Article

C2 - 16088144

AN - SCOPUS:23944514049

VL - 20

SP - 192

EP - 197

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

SN - 1420-8008

IS - 2-3

ER -